The Effect of Canagliflozin Dose on Renal and Cardiovascular Outcomes in Type 2 Diabetes and High Cardiovascular Risk
Authors' conclusion
In this post hoc analysis of the CANVAS trial, we did not observe evidence of a dose-dependent effect of canagliflozin on renal or cardiovascular outcomes. Both doses reduced the risk of kidney events versus placebo
Study context
- Population
- Patients with T2D and high cardiovascular risk in the CANVAS trial
- Participants
- 4,330 patients
- Comparison
- Canagliflozin 300 mg vs 100 mg
- Primary endpoint
- Composite of:
- Doubling of serum creatinine
- Renal failure
- Death due to renal cause
Methodological detailspost hoc analysis, participant-level data, Cox proportional hazards models
- Post hoc analysis
- Participant-level data
- Cox proportional hazards models
Primary result
As reported in the abstract
Composite renal endpoint:
- Doubling of serum creatinine
- Renal failure
- Death due to renal cause
Each group vs placeboHazard ratio (95% CI)P value
100 mg
0.49(0.25–0.95)
P = 0.03300 mg
0.41(0.20–0.83)
P = 0.01Secondary outcomes
Secondary endpoints: composite CV endpoint, hospitalisation for HF, all-cause mortality, progression or regression of albuminuria
- No difference between the two doses in any of the secondary endpoints
Safety
Safety (incl. serious hyperkalaemia and acute kidney injury)
- No added safety concerns identified with either dose
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
The Effect of Canagliflozin Dose on Renal and Cardiovascular Outcomes in Type 2 Diabetes and High Cardiovascular Risk. Diabetes Obes Metab. Published 31 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →